Dis Markers. 2013;35(4):267-72. doi: 10.1155/2013/912304.
Despite the advances that have been made in the fields of molecular and cell biology, there is still considerable debate explaining how the breast cancer cells progress through carcinogenesis and acquire their metastatic ability. The lack of preventive methods and effective therapies underlines the pressing need to identify new biomarkers that can aid early diagnosis and may be targets for effective therapeutic strategies. In this study we explore the pituitary tumor-transforming gene 1 (PTTG1) expression in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Three human cell lines, 184B5 derived from normal mammary epithelium, HCC70 from a primary ductal carcinoma, and MDA-MB-361 from a breast metastasis, were used for quantifying PTTG1 mRNA expression. The PTTG1 immunohistochemical expression was carried out on specimens taken from eight patients with invasive ductal breast cancer who underwent surgical treatment and followup for five years retrospectively selected. The study demonstrated that PTTG1 is expressed gradually in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Our findings suggest that the immunohistochemical evaluation of PTTG1 expression might be a powerful biomarker of recognition and quantification of the breast cancer cells in routine pathological specimens and a potential target for developing an effective immunotherapeutic strategy for primary and metastatic breast cancer.
尽管在分子和细胞生物学领域已经取得了进展，但仍有大量争论来解释乳腺癌细胞如何通过癌变进展并获得转移能力。缺乏预防方法和有效的治疗方法突显了确定新的生物标志物的迫切需要，这些生物标志物可以帮助早期诊断，并且可能成为有效治疗策略的靶点。在这项研究中，我们探讨了垂体肿瘤转化基因 1（PTTG1）在原发性导管乳腺癌、淋巴结浸润和远处转移中的表达。我们使用了三个人类细胞系，184B5 源自正常乳腺上皮，HCC70 源自原发性导管癌，MDA-MB-361 源自乳腺癌转移，用于定量 PTTG1 mRNA 表达。我们对 8 名接受手术治疗并进行了五年回顾性随访的浸润性导管乳腺癌患者的标本进行了 PTTG1 免疫组织化学表达检测。研究表明，PTTG1 在原发性导管乳腺癌、淋巴结浸润和远处转移中逐渐表达。我们的研究结果表明，PTTG1 免疫组织化学表达的评估可能是识别和量化常规病理标本中乳腺癌细胞的有力生物标志物，也是开发针对原发性和转移性乳腺癌的有效免疫治疗策略的潜在靶点。
